The gut microbiota is a highly intricate community in the gastrointestinal tract of humans that comprises approximately 10 to 100 trillion microorganisms (1, 2), encompassing fungi, bacteria, viruses, and parasites (3). The collective genome of the human gastrointestinal tract is known as the gastrointestinal microbiome (4). While the human genome is estimated to consist of approximately 23,000 coding genes, the gastrointestinal microbiome harbors over 3 million coding genes. These genes have the capacity to generate thousands of metabolites that influence the host’s health and disease progression through intricate biological interactions (5). The primary metabolites produced by the gut microbiota consist of short-chain fatty acids (SCFAs), tryptophan, bile acids (BAs), lipopolysaccharides (LPS), and indole derivatives (6–10). The gut microbiota plays a crucial role in the human body, not only pertaining to intestinal health but also exerting influence on the pathogenesis and progression of various diseases as well as immune system development (11–14).

Liver cancer is classified into primary and secondary types. Primary liver cancer is a highly malignant tumor that accounts for the majority of cases. HCC is the most common primary liver cancer, accounting for approximately 90% of cases (15). There are a number of staging systems for HCC that comprehensively assess the size, number, and aggressiveness of the tumor, as well as the overall health of the patient, in order to better guide treatment and assess prognosis. For example, the American Association for the Study of Liver Diseases (AASLD) guidelines, the World Health Organization (WHO) staging system, and the Barcelona Clinical Liver Cancer Staging (BCLC) system, which is recognized as one of the most effective staging methods due to its accuracy and practicality (16). In the BCLC staging system, early HCC refers to stages 0 and A, while middle and late HCC correspond to stages B, C and D. Early HCC can be completely cured by radical means such as hepatectomy and liver transplantation, but about 70% of patients have progressed to the middle and late stages at the time of diagnosis and are unable to undergo surgery (16). Therefore, non-surgical treatment has become the main treatment method for patients with advanced HCC. Non-surgical treatment is divided into local (interventional, ablative, radiotherapy) and systemic therapy (molecular targeting, immunotherapy). Among them, immune checkpoint inhibitors (ICIs) are the focus of current HCC immunotherapy research. They can not only block the immune escape of tumor cells, but also activate the function of T cells and enhance the immune surveillance and killing ability of T cells to generate immune response (17). Common immune checkpoints include PD-1, PD-L1, and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Currently PD-1/PD-L1 inhibitors approved for the treatment of HCC include sindilizumab, karelizumab, atezolizumab, durvalumab, etc. CTLA-4 inhibitors include terelizumab, and these inhibitors have been shown to be effective in some patients with advanced HCC (18). In addition, a combination of atezolizumab and bevacizumab (Atez/Bev) is recommended as first-line treatment for patients with advanced HCC (19).

The main causes of HCC are viral infections, such as chronic hepatitis B (20) and hepatitis C (21) viral infections. However, the introduction of the hepatitis B vaccine has diminished the role of viral infection as the primary precursor of HCC (22). More than 90% of HCC cases currently occur in patients with cirrhosis (23), cirrhosis is widespread worldwide and can be caused by different causes, such as obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), excessive alcohol consumption, hepatitis B or C infections, autoimmune diseases, cholestatic diseases, and iron or copper overload (24). Notably, a recent systematic review and meta-analysis clearly showed that the prevalence of sarcopenia in HCC patients was approximately 39%, and that sarcopenia was independently associated with decreased overall survival and progression free survival in HCC, independent of treatment modalities (25). On a related note, another systematic review and meta-analysis clearly indicated that the intestinal microbiota alpha diversity was significantly lower in patients with sarcopenia compared to non-sarcopenia groups (26). These findings underscore the complex interplay between metabolic health, muscle mass, and gut microbiota in HCC progression.

Akkermansia muciniphila (A. muciniphila) is a symbiotic bacterium residing in the intestinal mucosal layer that holds great potential for use as a probiotic (27). In a study on A. muciniphila and HCC, dysbiotic animals with HCC exhibited an intrahepatic immunosuppressive microenvironment characterized by intestinal barrier damage, bacterial translocation-induced monocyte myeloid-derived suppressor cell (MDSC) expansion, and inhibition of CD4+T and CD8+T cells, but they were reversed upon treatment of animals with A. muciniphila. Therefore, the absence of A. muciniphila in the intestine may contribute to the progression of liver diseases such as hepatitis and liver fibrosis toward HCC (28).

In 1992, the Food and Agriculture Organization of the United Nations defined resistant starch as “the collective term for starch and its degradation products that evade absorption by the small intestine in healthy individuals” (29). An experimental study using resistant starch as a dietary supplement suggests that alterations in the gut microbiome may mediate the progression of MASLD. Specifically, compared with the control group, the concentration of triglycerides in the liver of the resistant starch intervention group was significantly reduced (9.08%), the specific mechanism of which is that resistant starch reduces Bacteroides stercoris, the intestinal bacteroides that is significantly related to the content of triglycerides in the liver and liver enzymes (30).

Yujun et al. discovered that soluble fiber inulin was more effective than insoluble fiber cellulose in inhibiting the progression of metabolic dysfunction-associated steatohepatitis (MASH) in mice (31). It reduces hepatic steatosis, necrotizing inflammation, edema and fibrosis. The specific mechanism is that the use of inulin leads to the enrichment of distasonis in symbiotic parabacteroides, and these symbiotic parabacteroides are able to restore intestinal barrier function through the production of pentaconic acid by inulin, thereby reducing the expression of serum lipopolysaccharide and liver pro-inflammatory cytokines (31). Similarly, another group demonstrated that consumption of inulin caused alterations to the gut microbiota, characterized by enrichment in Bacteroides and an increase in concentrations of SCFAs, particularly acetate, within portal venous blood. Acetate inhibits the progression of MASLD or MASH through the regulation of liver lipid metabolism and affects insulin sensitivity via activation of free fatty acid receptor 2 in hepatic cells (32). In addition, we have summarized important clinical trials over the past 17 years on improving gut microbiota for the treatment of MASLD, MASH, alcohol associated chronic liver disease, and cirrhosis ( Table 1 ).

Dysregulation of the gut microbiota can result in increased intestinal permeability, thereby triggering microbial translocation and enhancing liver exposure to microbiota-derived products and metabolites that have an array of effects on the progression of HCC (33). The primary microbiota-derived SCFAs are acetic acid, propionic acid, butyric acid (34), and valeric acid (35). Studies have demonstrated that there is a reduction in the abundance of butyrate-producing bacteria in early-stage HCC. In addition, supplementation with butyrate can activates calcium-signaling pathways in HCC tumor cells, leading to dysregulation of calcium homeostasis and generation of reactive oxygen species, ultimately, this calcium-signaling cascade inhibits the proliferation and migration of HCC tumor cells (36) ( Figure 1A ). Additionally, the depletion of intestinal flora can hinder the metabolism of tryptophan in the intestine, leading to the accumulation of tryptophan and ultimately inhibiting the development of HCC (37). This process is mediated by the activation of aromatic hydrocarbon receptors by accumulated tryptophan and by inhibition of sterol regulatory element-binding protein 2 expression ( Figure 1B ).

Abnormal BAs metabolism is also closely associated with the progression of HCC and largely involves secondary BAs. The occurrence and development of HCC is a multifaceted process, and recent studies consistently indicate that the gut microbiota is significantly involved in modulating HCC signaling pathways. Acetate production by Bifidobacterium pseudolongum has been found to exert inhibitory effects on MASLD-associated HCC. Specifically, acetate is transported via the portal vein to the liver, where it selectively binds to GPR43 (G-protein coupled receptor 43) on HCC tumor cells. Activation of GPR43 suppresses the interleukin 6/Janus kinase 1/signal transducer and activator of transcription 3 signaling pathway, thereby impeding progression of MASLD-associated HCC (38) ( Figure 1C ). Research conducted by Yu Jun at the Chinese University of Hong Kong revealed that valeric acid produced by Lactobacillus acidophilus effectively reduced the mRNA and protein expression levels of markers associated with the Rho-GTPase (where Rho = Ras homology) pathway in mouse livers. Valeric acid was also found to inhibit Rho-GTPase signaling by binding to GPR41/43 receptors on hepatocyte surfaces, thereby suppressing MASLD-associated HCC (39) ( Figure 1D ).

Plant extracts can also affect HCC by modulating the production of metabolites within the gut microbiota. For instance, echinacea polysaccharide (EPP) possesses a diverse range of pharmacological activities, encompassing anti-inflammatory, immunomodulatory, and antineoplastic activities (40). Recent studies in mice have demonstrated the efficacy of EPP in attenuating hepatic damage induced by HCC, suppressing HCC proliferation, and inducing apoptosis. At a mechanistic level, EPP treatment caused a significant increase in the abundance of propionic acid- and butyric acid-producing gut microbes, such as Coprococcus, Clostridium, and Roseburia. This change in the gut microbiota promoted the expression of intestinal tight junction proteins and thus promoted intestinal repair, thereby inhibiting the leakage of the intestinal microbiota metabolite LPS. Consequently, in HCC tumor cells from mice, the Toll-like receptor 4/nuclear factor kappa-light-chain-enhancer of activated B cells (TLR4/NF-κB) pathway was inhibited, and the expression of inflammatory factors (e.g., interleukin 16 (IL-16)) and migration factors (e.g., matrix metalloproteinase-2) was reduced. Ultimately, these changes prevented the survival of HCC tumor cells (40) ( Figure 1E ).

It has also been shown that the gut microbiota can influence HCC through TLR4, and that hereditary TLR4 inactivation, intestinal sterilization, or sterility can reduce the incidence of HCC by approximately 80%. This reduction is primarily mediated by LPS (41).

Various immune cells in the tumor microenvironment play an important role in tumor development, invasion and metastasis. The TME of HCC comprises cancer cells, immune cells, cancer-associated fibroblasts, cytokines, chemokines, and other components (42). Immune cell populations within the TME include T cells, B cells, dendritic cells (DCs), NK cells, M1 macrophages, M2 macrophages, and MDSCs (43). We comprehensively summarize the regulatory role of gut microbiota on immune cells in HCC TME and illustrate how optimizing gut microbiota affects immune cells in HCC TME.

Antibiotics are a class of drugs that can inhibit the growth of or kill microorganisms and are widely used in the treatment of various infectious diseases (73–75). In recent years, there has been a growing focus on the correlation between antibiotics and cancer, and antibiotics have been identified as potentially supporting cancer treatment (76). However, the use of antibiotics to enhance the gut microbiota and consequently improve HCC immunotherapy has not been clinically documented. However, retrospective studies have indicated that antibiotics may affect HCC immunotherapy. One study encompassed all patients with advanced HCC who received ICIs treatment (including nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019, the findings revealed that antibiotic administration within a 30-day period before and after commencing ICIs treatment was associated with increased cancer-related mortality and overall mortality (77).

Relatedly, antibiotic usage was found to affect the efficacy of atezolizumab in combination with bevacizumab (denoted as “T + A therapy”) as a first-line standard treatment for unresectable HCC. Specifically, patients who received T + A therapy without antibiotics had a significantly longer progression-free survival and overall survival than their counterparts who received T + A therapy with antibiotics (78). However, some studies have suggested that patients with HCC may benefit from ICIs and antibiotic treatment. For example, a higher objective response rate was observed among patients with HCC who received early antibiotic treatment (within 30 days before or after ICIs treatment). However, the underlying mechanism was not elucidated (79).

In addition to affecting immunotherapy, the use of antibiotics also impacts the gut microbiome, thereby influencing tumor size in HCC mouse models. Moreover, antibiotics can alter the structure of the gut microbiome, further modulating immune cell function, ultimately playing a significant role in the onset and progression of HCC. For example, in 2010, Yu et al. showed that treatment of a mouse model of HCC with a combination of antibiotics (amoxicillin, vancomycin, neomycin sulfate, and metronidazole) depleted host bacteria and thereby impeded progression of HCC. The size and quantity of nodules in the antibiotic treatment group were significantly decreased compared with those in the control group (80). Other researchers have found that the combination of antibiotics (vancomycin, cefoperazone or ampicillin, neomycin, metronidazole, and vancomycin) inducing dysregulation of the gut microbiota in HCC patients can lead to a significant increase in IL-25 concentrations. The underlying mechanism involves dysregulated gut microbiota stimulating colon proliferative epithelial cluster cells to secrete large amounts of IL-25. Subsequently, IL-25 promotes HCC progression by inducing replacement activation of macrophages and the secretion of C-X-C motif chemokine ligand 10 within TME ( Figure 2D ) (81).

Another group utilized a transgenic mouse model of MYC to induce spontaneous HCC and administered an antibiotic mixture containing vancomycin, neomycin, and imipenem + cilastatin in drinking water. They discovered that compared with untreated MYC mice, antibiotic-treated MYC mice exhibited a gradual decrease in HCC incidence. Further investigations revealed that the gut microbiota controlled the accumulation of CXCR6+ liver NKT cells by regulating concentrations of chemokine CXCL16 in hepatic sinus endothelial cells by using BAs as signaling molecules. The accumulated NKT cells exhibited an activated phenotype and produced large amounts of IFN-γ, which effectively inhibited HCC tumor growth (82) ( Figure 2E ).

The Food and Agriculture Organization of the United Nations and the World Health Organization define probiotics as “living microorganisms that, when administered in adequate quantities, confer health benefits on the host” (83, 84). The main types of probiotics include Bifidobacterium, Bacillus subtilis, and lactic acid bacteria.

A groundbreaking study demonstrated that oral probiotics effectively enhance gut microbiota homeostasis in patients with cancer, thereby improving their response to immunotherapy. Specifically, the use of the probiotic drug CBM588 as an adjuvant significantly enhanced both the median progression-free survival and response rate in patients with metastatic renal cell carcinoma who were treated with nebuliumab, a PD-1 inhibitor, combined with ipilimumab, a CTLA-4 inhibitor. The median progression-free survival was increased by nearly fourfold, and the partial response rate was increased from 20% to 58% (85). The impact of probiotics on tumor immunotherapy has also been demonstrated in melanoma. Specifically speaking, the frequency of interferon-gamma (IFN-γ)-positive CD8+T cells in the probiotic-treated mouse tumors exhibited a significant reduction compared to the control group (86). Although there are no clinical studies on the effect of probiotics on HCC immunotherapy, there have been studies showing that the combination of probiotics and ICIs may also have an impact on HCC treatment.

However, a certain number of studies have been carried out on the effects of probiotics on HCC tumor cells and immune cells in the HCC TME. A randomized clinical trial of surgical intervention in patients with HCC showed that administration of probiotics significantly enhanced intestinal barrier function by increasing the abundance and diversity of beneficial bacteria and inhibiting the proliferation of harmful bacteria (87). It has also been demonstrated that various probiotics, including L. rhamnosus GG, B. longum, and Lactobacillus casei, affecting the incidence and progression of HCC. These probiotics mitigate the risk of HCC through diverse mechanisms, such as modulation of gut microbiota equilibrium, inhibition of HCC cell proliferation, attenuation of inflammatory responses, and regulation of immune function (88). In addition, probiotics can promote epigenetic modification of host genes, thereby reducing the progression of HCC (89).

More interestingly, the administration of probiotic fermented milk was found to attenuate the expression of rasp-21, c-myc, cyclin D1, and Bcl-2 in rat models of HCC, thereby impeding tumor progression (90). Similarly, Li et al. showed that Pro-hep, a probiotic formulation consisting of L. rhamnosus GG, live Escherichia coli Nissle 1917, and heat-inactivated VSL#3 (in a ratio of 1:1:1), suppressed HCC development in a murine model. Pro-hep reduced tumor weight and size by 40% in mice. It was determined that Pro-hep attenuated Th17 cell polarization within HCC tumors and downregulated the production of the pro-inflammatory vascular growth factor IL-17, thereby impeding HCC tumor progression ( Figure 2F ). Furthermore, Pro-hep increased the abundance of SCFA-producing bacteria (91).

FMT is a procedure in which stool from a healthy donor is transferred into the gastrointestinal tract of a recipient. A fecal graft consists of approximately 55% microbes and 24% soluble components, including mucus, fat, protein, small molecules, and SCFAs (92). In 2014, FMT was approved for the treatment of recurrent Clostridium difficile infections and demonstrates an approximate effectiveness rate of 90% in eliminating such infections (93). Moreover, FMT has proven efficacious in preventing the recurrence of such infections. The efficacy of FMT in the treatment of liver diseases, such as MASLD and alcoholic hepatitis, has also been demonstrated. For instance, Gomez-Hurtado et al. found that FMT from a healthy donor to 47 patients diagnosed with MASLD led to a significant amelioration of their clinical symptoms. Similarly, in 2017, Philips et al. published a compelling study demonstrating that a patient with severe alcoholic hepatitis exhibited significant clinical and biochemical improvements after undergoing FMT (94).

In addition, the gut microbiota of eight patients with advanced HCC who were treated with nabuliumab exhibited distinct β diversities, In non-responders, bacteria such as pneumococcus, Escherichia coli, L. regenerans, Streptococcus mutans, Enterococcus faecium, Streptococcus gordonii, Veillonella atypica, Granulicatella sp. and Trichuris trichiura were prevalent. In contrast, in responders, Citrobacter freundii, Azospirillum sp., and Enterococcus durans were prevalent (95). Furthermore, Ponziani et al. conducted a prospective study on 11 patients with HCC who were treated with tremelimumab and/or durvalumab. Their findings indicate that the relative abundance of Akkermansia was higher in responders than non-responders, while the relative abundance of Enterobacteriaceae decreases in responders (96). In summary, although the effectiveness of FMT in treating HCC with ICIs has not been clinically proven, the distinct fecal flora composition observed in ICIs responders and non-responders among patients with HCC implies that FMT has the potential to enhance the efficacy of HCC immunotherapy. In addition, there are two clinical trials underway to investigate this ( Table 2 ).

However, there is currently one study on the impact of FMT on immune cells in the TME of HCC mice. Lactobacillus reuteri is a well-known probiotic that has positive effects on various diseases, such as constipation, MASLD, metabolic syndrome, acute diarrhea, allergic rhinitis, and asthma, and enhances ICIs-based treatment of melanoma (97–100). Recent research showed that a reduction in the abundance of enteroborne L. reuteri and in concentrations of its metabolite (acetic acid) are involved in the development of HCC. For example, transplantation of feces treated with antibiotics and supplemented with L. reuteri or wild-type mice feces into mice models of HCC (in which the abundance of L. reuteri and concentrations of acetic acid were significantly reduced) resulted in a decrease in tumor quantity and size. Acetate produced by L. reuteri inhibited interleukin-17A-producing ILC3 cells in HCC by inhibiting histone deacetylase activity and inducing SRY-box transcription factor 13 acetylation (101). Other studies have shown that interleukin-17A can cause MASH and HCC, while interleukin-17A inhibitors can prevent MASH and HCC in high-risk patients (102) ( Figure 2G ). However, FMT has some disadvantages, such as the risk of disease transmission from a donor to a recipient, and variations in patient acceptance (103).

The term prebiotic is rather recent, as it was first defined in 1995 as “an indigestible food component that selectively stimulates the growth or activity of specific bacteria in the gut to enhance host health” (104). Prebiotics are abundant in various plants, such as onions and garlic, and contribute to the production of SCFAs (105). Currently, fructooligosaccharides and inulin are among the most extensively studied prebiotics. These compounds have demonstrated the ability to promote proliferation of the beneficial bacteria Bifidobacterium, which has potential anticancer properties (106).

A robust inverse association was found between the incidence of liver cancer and consumption of vegetables abundant in inulin and fructooligosaccharides, such as celery, mushrooms, and leeks. This association suggests that prebiotics exert a potent protective effect against liver cancer (107). Additionally, a meta-analysis of a total of 3,912 patients diagnosed with HCC demonstrated that each 100-g-per-day increase in vegetable consumption was associated with an 8% reduction in the risk of developing HCC (108). Prebiotics play a crucial role in the prevention of HCC and the mitigation of risks of HCC. However, there is currently insufficient evidence to support the hypothesis that prebiotics enhance immune cell function in the HCC TME or improve HCC immunotherapy by modulating the composition of the gut microbiome. Therefore, further comprehensive studies are needed to verify whether these hypotheses hold true.

Diet fundamentally shapes the relationship between humans and their gut microbiota, as dietary nutrients profoundly influence the health and viability of trillions of gut microbes (109). Therefore, the effects of diet on gut microbiota may significantly regulate the progression of various diseases.

For instance, it was found in mice that a high-sugar, high-fat diet can lead to changes in the composition of the gut microbiota, resulting in enhanced expression of pro-inflammatory markers TNF-α, IL-2, peroxisome proliferator-activated receptor gamma, and NF-κB within the intestinal tract. These changes triggered tissue inflammation and pathological changes, ultimately leading to sustained inflammation-induced damage in both the small intestine and colon (110). Similarly, it was found that a high-cholesterol diet caused gut microbiota changes in mice and promoted the progression of liver steatosis, hepatitis, liver fibrosis, and HCC. In addition, germ-free mice also showed liver lipid accumulation after ingesting stool samples from the high-cholesterol diet group (111).

Furthermore, prolonged administration of fermentable fiber to TLR5 knockout mice (T5KO) resulted in hyperbilirubinemia and jaundice-associated HCC. Similarly, extensive hepatic inflammation and infiltration of neutrophils, macrophages, and T cells were observed in the livers of mice fed an ICD (an open-source diet containing 7.5% inulin and 2.5% cellulose). Additional investigation revealed that the gut microbiota of these mice exhibited an increased abundance of fibrous fermenters and Proteobacteria, a decreased abundance of Firmicutes, and a reduction in species richness and α-diversity. Moreover, compared with the control group, cecal butyrate concentrations were significantly increased in ICD-fed mice. However, antibiotic-treated T5KO mice showed immunity to ICD-induced HCC, suggesting that the etiology of this form of HCC is microbially dependent, although this remains to be mechanistically confirmed (112). Therefore, despite the numerous advantages of consuming foods rich in soluble fiber, they should be consumed with caution, as they may trigger HCC initiation. However, there is currently a lack of sufficient research on the impact of diet on immune cells in the HCC TME and its potential role in improving immunotherapy. Further in-depth studies in these areas are urgently needed in the future.

Another way to improve the health of the gut microbiota is through the use of traditional Chinese medicine preparations. For example, xiayuxue decoction XYXD (which primarily consists of Rheum officinale Baill, Prunus persica (L.) Batsch, and Eupolyphaga sinensis Walker), was found to trigger the immune action of NKT cells against HCC by regulating the gut microbiota. Its mechanism of action involves increasing the abundance of Bacteroides and Lactobacillus to promote the production of bile salt hydrolase, which facilitates the conversion of conjugated BAs into primary BAs. Simultaneously, it also reduces the abundance of Eubacterium and hinders the conversion of primary BAs into secondary BAs. The increase in the concentrations of primary BAs from both pathways ultimately triggers CXCR6 to recruit NKT cells in the liver, which produce IFN-γ, which has an inhibitory effect toward HCC tumor cells (113) ( Figure 2H ). Other findings also highlight the therapeutic potential of traditional Chinese medicines in regulating gut microbiota to influence cancer progression. For example, Pian Zai Huang can inhibit the development of colorectal cancer by regulating gut microbiota composition and metabolite levels, promoting the improvement of intestinal barrier function, and inhibiting carcinogenic and pro-inflammatory pathways (114).

In addition to common methods such as probiotics supplementation and dietary adjustments, phage therapy, as an emerging strategy, opens up a new path for optimizing the gut microbiome. Bacteriophages possess high specificity, excellent manipulability, non-toxicity, and nanometer-scale characteristics, making them highly promising vectors in the fields of targeted therapy and cancer immunotherapy. Currently, cancer research faces numerous challenges, such as damage to healthy cells, suboptimal targeting efficiency, biological barriers, and the emergence of drug resistance. In this context, bacteriophage therapy or the use of bacteriophages as delivery vectors for treatment strategies has become particularly urgent and necessary (115).In addition, as a natural biopreparation, bacteriophages have a relatively short survival time in the human body. Unlike antibiotics, they do not remain in the body for long periods, which results in relatively fewer toxic side effects.

Phage therapy has been studied in diseases such as breast cancer, lung adenocarcinoma, colorectal cancer, hepatocellular carcinoma, B-cell lymphoma, multiple myeloma, cervical cancer, neuroendocrine pancreatic tumors, melanoma, chondrosarcoma, and glioblastoma. Currently, the mechanisms of action of phage-based cancer therapies mainly involve two key aspects. On one hand, phages can trigger the body’s immune response to precisely target and destroy cancer cells. On the other hand, phages can serve as efficient targeted delivery carriers, enabling various therapeutic agents to be directly and accurately delivered to the target cells (115).

It is also worth mentioning that numerous studies are currently focused on using phages to improve the gut microbiota for disease treatment. For example, research by Yuan Jing and colleagues revealed that in NAFLD, some cases of endogenous alcoholic fatty liver disease caused by high ethanol-producing Klebsiella pneumoniae were studied using a mouse model. They found that the clinically promising short-tail virulent phage phiW14 could specifically target the high ethanol-producing Klebsiella pneumoniae, blocking the production of endogenous ethanol, regulating immune responses and metabolism, and alleviating liver damage, providing an efficient and specific therapeutic approach for endogenous alcoholic fatty liver disease without affecting the gut microbiota structure (116).

Another study indicates that in colorectal cancer (CRC) patients, the number of Fusobacterium nucleatum is increased in feces and enriched at the tumor site, while butyrate-producing bacteria such as Faecalibacterium prausnitzii are reduced. Fusobacterium nucleatum helps CRC cells resist chemotherapy through the TLR4-Myd88 pathway, while butyrate secreted by Faecalibacterium prausnitzii inhibits CRC cell growth. The study also found that Fusobacterium nucleatum-specific phages isolated from human saliva, combined with drug-loaded nanoparticles, formed a nanomedicine that was safe in piglets. In mice, the nanomedicine was able to accumulate at CRC tumor sites, significantly extend the survival of CRC mice, reduce intestinal adenomas in Apc mice, and also decrease the number of Fusobacterium nucleatum, increase the abundance of Faecalibacterium prausnitzii, and elevate butyrate levels in the colon (117).

Although there is currently no research specifically exploring the use of phages to optimize the gut microbiota to improve immune cell function in the HCC TME or advance immunotherapy, existing studies have provided valuable insights. In the future, phages are expected to become a key intervention in HCC treatment. For example, research can analyze the interaction between phages and the gut microbiota at the molecular and cellular levels, use high-throughput screening to identify effective strains, and develop personalized treatment strategies based on multi-omics technologies. By combining basic and clinical trials, exploring the combination of phages with other therapeutic approaches may optimize treatment plans, improve patient prognosis, and open up new pathways for clinical HCC treatment.